Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 15/20 | 0.63 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27214233 | 1.00 | SLC40A1 (0.63) | SLC40A1MCL1MEN1KMT2ATDP1 | |
| SCHEMBL30925404 | 0.87 | SLC40A1 (0.62) | SLC40A1MCL1MEN1KMT2ATDP1 | |
| SCHEMBL27214167 | 0.87 | SLC40A1 (0.65) | SLC40A1MCL1MEN1KMT2ATDP1 | |
| SCHEMBL30925582 | 0.87 | SLC40A1 (0.65) | SLC40A1MCL1MEN1KMT2ATDP1 | |
| SCHEMBL27214240 | 0.87 | SLC40A1 (0.62) | SLC40A1MCL1MEN1KMT2ATDP1 | |
| SCHEMBL30925442 | 0.84 | GLO1 (0.60) | SLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL27214304 | 0.84 | GLO1 (0.60) | SLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL30925417 | 0.83 | MCL1 (0.63) | SLC40A1MCL1 | |
| SCHEMBL11973412 | 0.78 | SLC40A1 (1.00) | SLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL29255663 | 0.77 | SLC40A1 (0.70) | SLC40A1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | SLC40A1 3357/4885MCL1 3427/4885MEN1 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.